The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Up 25% Today .
Last chance to sell tomorrow.
Clive Dix CEO is up on his 8 April buy below.
Brought 485,320 shares yesterday at 10.3p
Share Price: 12.00......Bid: 10.30....Ask: 10.80....Change: 2.575 (27.32%)
Spread: 0.50 (4.854%).
RNS yesterday.
Clive Dix CEO .
Brought 485,320 shares yesterday at 10.3p
A further -15% down today will not be allowed to stay in ISA , if you do not sell.
AIM shares just not worth risking money on .
Wednesday 27th Mar 2024
This from before the Easter break ,
C4X Discovery seeks AIM delisting but half-year revenue skyrockets
(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.
C4X shares dropped 24% to 10.00 pence on late on Wednesday morning in London.
The Manchester, England-based drug discovery company will seek shareholder approval to delist from AIM at a general meeting on April 5. It expects the cancellation to take effect on the morning of April 26.
Following the delisting, C4X intends to re-register as a private limited company.
Chief Executive Officer Clive Dix said the decision follows "an extensive review and deliberation to ascertain the most effective way to maximise shareholder value in the longer term and increase the potential for [our] long-term success".
He added that "the recent downturn in the financial markets has adversely impacted our share price, and with it, our future ability to raise funds in the public markets...we can potentially access a larger quantum of future funding required to accelerate our strategy as a private company".
Also on Wednesday, C4X released its results for the six months to January 31.
The company swung to a GBP17.8 million pretax profit, following its GBP5.2 million loss in the first half of financial 2023.
Revenue, meanwhile, soared to GBP24.6 million from GBP1.7 million.
C4X said this reflected receipt of GBP15.9 million from selling the rights to its Orexin-1 receptor antagonist to Indivior PLC in August, and a USD11 million or GBP8.7 million milestone payment from AstraZeneca PLC. The latter, received in early January, stemmed from preclinical progress of C4X's NRF2 Activator programme which it licensed out to AstraZeneca in November.
Research & Development expenses remained stable at GBP5.2 million, "reflecting focused investment in key drug discovery programmes focused on immune-inflammatory diseases."
Looking ahead, C4X believes it is "in a strong financial position with the potential for further milestone payments over the next 18 months".
It said that once it officially becomes a private company, it will be able to "accelerate our strategy and...maximise revenue from our portfolio", assuming it can access those larger pools of potential funding.
I saw the below post by gggg21 , I have to many losing AIM shares , I have read on other BBs that you can not go short on these types of shares , and this one having a smaller free float then others .
What is the truth of shorting on AIM .
RE: So...15 Dec 2023 08:10
Amazing how that one short opened this morning has pushed it down but so difficult to buy.
Up 13% to 17.3p on the bid. 2.9% spread the ask is 17.8p.
Now above my buy price of 16.65p in hindsight the noticed 43% rise two days ago was a buy signal .
Two weeks ago on 18/12/23 I saw a new low of 8.41p ( 50 % down ) must be manipulation this payment was known to be coming ?
Bad luck for any who might of sold a week before Christmas day.
Saw these 43% up on this site *( D ) not showing as a riser on table , made me wonder if I did hold .
There is hope for my 80% losing positions .
This news must of been known to any big boys before today's RNS .
News today.
C4X receives USD11 million from AstraZeneca following NRF2 trials
C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.
The Manchester, England-based drug discovery company received USD11.0 million from the Cambridge, England-based pharmaceutical maker AstraZeneca.
The payment stems from preclinical progress of C4X's NRF2 Activator programme, an oral therapy for the treatment of inflammatory and respiratory diseases which AstraZeneca is developing following a agreement between the two in November.
In addition to a USD2.0 million upfront payment, the global licencing agreement for the NRF2 Activator entitles C4X to receive up to USD400.0 million in payments following preclinical, clinical development and commercial milestones. The deal also will grant C4X tiered mid-single digit royalties on future sales of the NRF2.
C4X Chief Executive Officer Clive Dix said: "This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation. We believe that our unique approach can deliver transformative oral therapies for patients suffering from immuno-inflammatory diseases. This is a great start to our year and we are confident of seeing further progress across our entire portfolio in 2024."
Shares in C4X were up 12% at 10.00 pence each in London on Wednesday morning.
By Hugh Cameron, Alliance News reporter
No idea ( can not see notes bar ) why I bought in 2021 , I see they recovered to 42p 4th January 2022 .
Less likely to of missed that if I had held on ( D ) .
I see there was a placing 11th August 2022 @ 25p no OO .
Topped up 11am for 16.65p 2% down today ( D ) brokers platform which was not allowed when I i first purchased these 24th August 2021.
( Wi ) That buy was at 30.03p showing as 43% down on the platform . ( I make it 45% down )
Took a slice in SCLP an hour before looks a good transfer of funds at midday this up a little from buy and SCLP down from the sale .